Literature DB >> 16364737

Filovirus assembly and budding.

Bettina Hartlieb1, Winfried Weissenhorn.   

Abstract

Filoviruses belong to the order of negative-stranded non-segmented RNA viruses and are classified into two genera, Ebola and Marburg viruses. They have a characteristic filamentous shape, which is largely determined by the matrix protein VP40. Although VP40 is the main driving force for assembly and budding from the host cell, the production of infectious virus involves an intricate interplay between all viral structural proteins in addition to cellular factors, e.g., those that normally function in multi-vesicular body biogenesis. As a consequence, assembly and budding steps are defined to specific cellular compartments, and the recent progress in understanding how the different components are assembled into stable enveloped virus particles is reviewed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16364737     DOI: 10.1016/j.virol.2005.09.018

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  64 in total

1.  Viral and host proteins that modulate filovirus budding.

Authors:  Yuliang Liu; Ronald N Harty
Journal:  Future Virol       Date:  2010-07-01       Impact factor: 1.831

2.  Identification of essential filovirion-associated host factors by serial proteomic analysis and RNAi screen.

Authors:  Kevin B Spurgers; Tim Alefantis; Brian D Peyser; Gordon T Ruthel; Alison A Bergeron; Julie A Costantino; Sven Enterlein; Krishna P Kota; R C Dutch Boltz; M Javad Aman; Vito G Delvecchio; Sina Bavari
Journal:  Mol Cell Proteomics       Date:  2010-08-11       Impact factor: 5.911

3.  Oligomerization of Ebola virus VP40 is essential for particle morphogenesis and regulation of viral transcription.

Authors:  T Hoenen; N Biedenkopf; F Zielecki; S Jung; A Groseth; H Feldmann; S Becker
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

4.  Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations.

Authors:  Jens H Kuhn; Stephan Becker; Hideki Ebihara; Thomas W Geisbert; Karl M Johnson; Yoshihiro Kawaoka; W Ian Lipkin; Ana I Negredo; Sergey V Netesov; Stuart T Nichol; Gustavo Palacios; Clarence J Peters; Antonio Tenorio; Viktor E Volchkov; Peter B Jahrling
Journal:  Arch Virol       Date:  2010-10-30       Impact factor: 2.574

5.  Molecular determinants of arenavirus Z protein homo-oligomerization and L polymerase binding.

Authors:  Maria Eugenia Loureiro; Maximiliano Wilda; Jesica M Levingston Macleod; Alejandra D'Antuono; Sabrina Foscaldi; Cristina Marino Buslje; Nora Lopez
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

Review 6.  Conformational plasticity of the Ebola virus matrix protein.

Authors:  Jens Radzimanowski; Gregory Effantin; Winfried Weissenhorn
Journal:  Protein Sci       Date:  2014-09-04       Impact factor: 6.725

7.  The cytoplasmic tails of Uukuniemi Virus (Bunyaviridae) G(N) and G(C) glycoproteins are important for intracellular targeting and the budding of virus-like particles.

Authors:  Anna K Overby; Vsevolod L Popov; Ralf F Pettersson; Etienne P A Neve
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

8.  Crystal structure of the Borna disease virus matrix protein (BDV-M) reveals ssRNA binding properties.

Authors:  Piotr Neumann; Diana Lieber; Sylke Meyer; Philipp Dautel; Andreas Kerth; Ina Kraus; Wolfgang Garten; Milton T Stubbs
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

9.  Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccine.

Authors:  Amy B Papaneri; John G Bernbaum; Joseph E Blaney; Peter B Jahrling; Matthias J Schnell; Reed F Johnson
Journal:  Virus Res       Date:  2014-12-04       Impact factor: 3.303

10.  Pathophysiology of Ebola Virus Infection: Current Challenges and Future Hopes.

Authors:  Andrea Rivera; Ilhem Messaoudi
Journal:  ACS Infect Dis       Date:  2015-03-30       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.